Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (avaa uuden ikkunan)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Lähde‎: Cancer 2013;119(21):3784-7.

Arkistoitu‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (avaa uuden ikkunan)

Low dose bolus aminocaproic acid: an alternative to platelet transfusion in thrombocytopenia? (avaa uuden ikkunan)

Chakrabarti S, Varma S, Singh S, Kumari S

Lähde‎: Eur J Haematol 1998;60(5):313-4.

Arkistoitu‎: PubMed 9654162

DOI‎: 10.1111/j.1600-0609.1998.tb01046.x

https://www.ncbi.nlm.nih.gov/pubmed/9654162 (avaa uuden ikkunan)

The use of antifibrinolytics in pediatric patients with hypoproliferative thrombocytopenia. (avaa uuden ikkunan)

Delaney M, Matthews DC, Gernsheimer TB

Lähde‎: Pediatr Blood Cancer 2017;64(12):e26641.

Arkistoitu‎: PubMed 28544698

DOI‎: 10.1002/pbc.26641

https://www.ncbi.nlm.nih.gov/pubmed/28544698 (avaa uuden ikkunan)

Preliminary experience with epsilon aminocaproic acid for treatment of intractable upper tract hematuria in children with hematological disorders. (avaa uuden ikkunan)

Kaye JD, Smith EA, Kirsch AJ, Cerwinka WH, Elmore JM

Lähde‎: J Urol 2010;184(3):1152-7.

Arkistoitu‎: PubMed 20650477

DOI‎: 10.1016/j.juro.2010.05.020

https://www.ncbi.nlm.nih.gov/pubmed/20650477 (avaa uuden ikkunan)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (avaa uuden ikkunan)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Lähde‎: Leuk Lymphoma 1995;19(1-2):141-4.

Arkistoitu‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (avaa uuden ikkunan)

Pediatric off-label use of recombinant factor VIIa. (avaa uuden ikkunan)

Alten JA, Benner K, Green K, Toole B, Tofil NM, Winkler MK.

Lähde‎: Pediatrics 2009;123(3):1066-72.

Arkistoitu‎: PubMed 19255041

DOI‎: 10.1542/peds.2008-1685

https://www.ncbi.nlm.nih.gov/pubmed/19255041 (avaa uuden ikkunan)

Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience. (avaa uuden ikkunan)

Bhat S, Yadav SP, Anjan M, Dinand V, Sachdeva A.

Lähde‎: Indian J Pediatr 2011;78(8):961-8.

Arkistoitu‎: PubMed 21328080

DOI‎: 10.1007/s12098-011-0364-6

https://www.ncbi.nlm.nih.gov/pubmed/21328080 (avaa uuden ikkunan)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (avaa uuden ikkunan)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Lähde‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

Arkistoitu‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (avaa uuden ikkunan)

Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label. (avaa uuden ikkunan)

Croteau SE, Nakar C, Neufeld EJ, Shapiro A, Cooper DL

Lähde‎: Pediatr Blood Cancer 2016;63(10):1822-8.

Arkistoitu‎: PubMed 27232114

DOI‎: 10.1002/pbc.26082

https://www.ncbi.nlm.nih.gov/pubmed/27232114 (avaa uuden ikkunan)

Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia. (avaa uuden ikkunan)

Das P, Carcao M, Hitzler J

Lähde‎: Pediatr Blood Cancer 2006;47(2):206-9.

Arkistoitu‎: PubMed 16007583

DOI‎: 10.1002/pbc.20467

https://www.ncbi.nlm.nih.gov/pubmed/16007583 (avaa uuden ikkunan)

A comprehensive review of rFVIIa use in a tertiary care pediatric center. (avaa uuden ikkunan)

Heller M, Lau W, Pazmino-Canizares J, Brandão LR, Carcao M

Lähde‎: Pediatr Blood Cancer 2008;50(5):1013-7.

Arkistoitu‎: PubMed 17960639

DOI‎: 10.1002/pbc.21375

https://www.ncbi.nlm.nih.gov/pubmed/17960639 (avaa uuden ikkunan)

Recombinant activated factor VII for severe gastrointestinal bleeding after chemotherapy in an infant with acute megakaryoblastic leukemia. (avaa uuden ikkunan)

Kurekci AE, Atay AA, Okutan V, Yavuz ST, Ozcan O

Lähde‎: Blood Coagul Fibrinolysis 2005;16(2):145-7.

Arkistoitu‎: PubMed 15741803

DOI‎: 10.1097/01.mbc.0000161569.66764.70

https://www.ncbi.nlm.nih.gov/pubmed/15741803 (avaa uuden ikkunan)

Off-label use of recombinant factor VIIa in pediatric patients. (avaa uuden ikkunan)

McQuilten ZK, Barnes C, Zatta A, Phillips LE; Haemostasis Registry Steering Committee

Lähde‎: Pediatrics 2012;129(6):e1533-40.

Arkistoitu‎: PubMed 22641758

DOI‎: 10.1542/peds.2011-2561

https://www.ncbi.nlm.nih.gov/pubmed/22641758 (avaa uuden ikkunan)

Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: the experience of the Hemostasis and Thrombosis Research Society (HTRS) registry (2004-2008). (avaa uuden ikkunan)

Neufeld EJ, Saxena K, Kessler CM, Cooper DL; HTRS Investigators

Lähde‎: Pediatr Blood Cancer 2013;60(7):1178-83.

Arkistoitu‎: PubMed 23335449

DOI‎: 10.1002/pbc.24472

https://www.ncbi.nlm.nih.gov/pubmed/23335449 (avaa uuden ikkunan)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (avaa uuden ikkunan)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Lähde‎: Med Oncol 2010;27(1):16-9.

Arkistoitu‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (avaa uuden ikkunan)

Successful treatment of acute lymphoblastic leukemia with l-asparaginase-induced intracranial hemorrhage to activated recombinant factor VIIa in a child. (avaa uuden ikkunan)

Ucar C, Caliskan U

Lähde‎: Pediatr Hematol Oncol 2006;23(4):339-45.

Arkistoitu‎: PubMed 16621776

DOI‎: 10.1080/08880010600631987

https://www.ncbi.nlm.nih.gov/pubmed/16621776 (avaa uuden ikkunan)

Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder. (avaa uuden ikkunan)

Yilmaz D, Karapinar B, Balkan C, Akisü M, Kavakli K.

Lähde‎: Pediatr Hematol Oncol 2008;25(4):301-11.

Arkistoitu‎: PubMed 18484474

DOI‎: 10.1080/08880010802016904

https://www.ncbi.nlm.nih.gov/pubmed/18484474 (avaa uuden ikkunan)

The use of DDAVP in children with bleeding disorders. (avaa uuden ikkunan)

Ben-Ami T, Revel-Vilk S

Lähde‎: Pediatr Blood Cancer 2013;60 Suppl 1:S41-3.

Arkistoitu‎: PubMed 23109357

DOI‎: 10.1002/pbc.24335

https://www.ncbi.nlm.nih.gov/pubmed/23109357 (avaa uuden ikkunan)

Treatment of refractory thrombocytopenic bleeding with 1-desamino-8-D-arginine vasopressin (desmopressin). (avaa uuden ikkunan)

Kobrinsky NL, Tulloch H

Lähde‎: J Pediatr 1988;112(6):993-6.

Arkistoitu‎: PubMed 3373409

DOI‎: 10.1016/s0022-3476(88)80234-8

https://www.ncbi.nlm.nih.gov/pubmed/3373409 (avaa uuden ikkunan)

The use of Tachosil as hemostatic sealant in nephron sparing surgery for Wilms tumor: preliminary observations. (avaa uuden ikkunan)

Mele E, Ceccanti S, Schiavetti A, Bosco S, Masselli G, Cozzi DA

Lähde‎: J Pediatr Surg 2013;48(3):689-94.

Arkistoitu‎: PubMed 23480936

DOI‎: 10.1016/j.jpedsurg.2013.01.019

https://www.ncbi.nlm.nih.gov/pubmed/23480936 (avaa uuden ikkunan)